Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 5/20 | 0.48 |
| ▸ | GSK3B | P49841 | 5/20 | 0.48 |
| ▸ | FLT3 | P36888 | 5/20 | 0.45 |
| ▸ | JAK2 | O60674 | 3/20 | 0.45 |
| ▸ | SRC | P12931 | 3/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9940843 | 0.98 | GSK3A (0.49) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9940842 | 0.98 | GSK3A (0.49) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL15400835 | 0.94 | GSK3A (0.54) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199393 | 0.91 | GSK3A (0.41) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9941696 | 0.88 | GSK3A (0.41) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL15401009 | 0.88 | GSK3A (0.41) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9970822 | 0.88 | GSK3A (0.41) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL9970866 | 0.86 | GSK3A (0.38) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199042 | 0.85 | GSK3A (0.51) | GSK3AGSK3BFLT3JAK2SRC | |
| SCHEMBL16199059 | 0.85 | GSK3A (0.51) | GSK3AGSK3BFLT3JAK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871774-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005192-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885FLT3 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.